phospholipase A2 group IIIGenealiases: GIII-SPLA2 · SPLA2III · sPLA2-III
Q-omics provides the consensus-scored PLA2G3 profile across patient tissues and cancer cell-line models. PLA2G3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PLA2G3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PLA2G3 RNA expression shows 9,882 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where PLA2G3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G3 survival associations across molecular data types. PLA2G3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G3 RNA expression–survival associations across cancer types. High PLA2G3 expression shows unfavorable associations in KIRC, KIRP, SKCM and LGG, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PLA2G3 RNA expression.
This table summarizes PLA2G3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PLA2G3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G3 shows lower tumor expression in KIRC, KIRP, LUAD and THCA and higher tumor expression in COAD and UCEC. The KIRC box plot shows higher PLA2G3 RNA expression in normal versus tumor tissue (log2 FC = −0.405, t-test p < 0.001).
This table shows molecular features associated with PLA2G3 in patient tissues and cancer cell lines. In patient samples, PLA2G3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLA2G3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
